BridgeBio Pharma (NASDAQ:BBIO) Announces Quarterly Earnings Results

BridgeBio Pharma (NASDAQ:BBIO) released its earnings results on Monday. The company reported ($0.78) EPS for the quarter, missing the consensus estimate of ($0.58) by ($0.20), FiscalAI reports. The business had revenue of $243.68 million for the quarter, compared to analysts’ expectations of $220.91 million. The firm’s revenue for the quarter was up 120.4% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.95) earnings per share.

Here are the key takeaways from BridgeBio Pharma’s conference call:

• Attruby net product revenue reached $222.4 million, up $150.9 million year over year and more than $35 million sequentially. Growth was led by treatment-naive, first-line patients, while the company expects additional support from kidney-protection data and real-world evidence.
• BridgeBio said Attruby is positioned to benefit from the failed CARDIO-TTRansform combination-therapy study, which it believes reinforces stabilizers as the first-line treatment backbone. Management expects clinical differentiation, including early outcomes and renal benefits, to support further share gains over the next 12–18 months.
• All three major pipeline programs advanced into regulatory review: BBP-418 for LGMD2I received priority review with a November 27, 2026 PDUFA date, encaleret for ADH1 received priority review with a May 8, 2027 target date, and infigratinib’s achondroplasia NDA was submitted. The company is building commercial infrastructure for potential launches over the next 12–18 months.
• Operating expenses rose to $335.7 million as BridgeBio invested in Attruby and preparations for three launches, though the operating loss improved 20% year over year to $107.1 million. Following a $1 billion preferred-equity financing, management expects operating results to remain roughly stable for several quarters before moving toward breakeven and cash generation in 2027.

BridgeBio Pharma Trading Up 0.2%

Shares of BBIO stock opened at $84.67 on Tuesday. The business’s 50-day moving average price is $76.07 and its 200-day moving average price is $73.03. BridgeBio Pharma has a 12 month low of $46.28 and a 12 month high of $93.42. The firm has a market capitalization of $16.55 billion, a price-to-earnings ratio of -22.64 and a beta of 0.96.

Insider Buying and Selling

In related news, Director Randal W. Scott sold 10,000 shares of the firm’s stock in a transaction that occurred on Friday, May 15th. The shares were sold at an average price of $67.15, for a total value of $671,500.00. Following the completion of the transaction, the director owned 11,589 shares in the company, valued at $778,201.35. This trade represents a 46.32% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Andrea Ellis sold 17,167 shares of BridgeBio Pharma stock in a transaction that occurred on Thursday, July 9th. The stock was sold at an average price of $84.00, for a total transaction of $1,442,028.00. Following the sale, the director owned 22,579 shares in the company, valued at approximately $1,896,636. This represents a 43.19% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 392,117 shares of company stock valued at $29,934,700 over the last three months. Insiders own 14.23% of the company’s stock.

Hedge Funds Weigh In On BridgeBio Pharma

A number of hedge funds have recently modified their holdings of the business. Commonwealth Equity Services LLC increased its holdings in BridgeBio Pharma by 4.9% in the fourth quarter. Commonwealth Equity Services LLC now owns 5,179 shares of the company’s stock valued at $396,000 after purchasing an additional 244 shares during the period. Xponance LLC lifted its holdings in BridgeBio Pharma by 2.2% during the 4th quarter. Xponance LLC now owns 12,536 shares of the company’s stock worth $959,000 after buying an additional 272 shares during the period. Smartleaf Asset Management LLC grew its position in shares of BridgeBio Pharma by 63.1% in the 4th quarter. Smartleaf Asset Management LLC now owns 739 shares of the company’s stock valued at $56,000 after buying an additional 286 shares during the last quarter. Global Retirement Partners LLC increased its stake in shares of BridgeBio Pharma by 271.5% in the fourth quarter. Global Retirement Partners LLC now owns 509 shares of the company’s stock valued at $39,000 after buying an additional 372 shares during the period. Finally, Vanguard Personalized Indexing Management LLC increased its stake in shares of BridgeBio Pharma by 2.6% in the fourth quarter. Vanguard Personalized Indexing Management LLC now owns 17,239 shares of the company’s stock valued at $1,319,000 after buying an additional 436 shares during the period. Institutional investors and hedge funds own 99.85% of the company’s stock.

Analysts Set New Price Targets

BBIO has been the topic of several analyst reports. Citigroup increased their price target on shares of BridgeBio Pharma from $82.00 to $93.00 and gave the stock a “neutral” rating in a research report on Thursday, July 16th. Truist Financial boosted their price objective on shares of BridgeBio Pharma from $95.00 to $102.00 and gave the company a “buy” rating in a research report on Wednesday, April 29th. Canaccord Genuity Group initiated coverage on BridgeBio Pharma in a research note on Wednesday, June 3rd. They set a “buy” rating and a $104.00 target price for the company. Mizuho reduced their target price on BridgeBio Pharma from $106.00 to $96.00 and set an “outperform” rating on the stock in a report on Tuesday, June 16th. Finally, Raymond James Financial lowered BridgeBio Pharma from an “outperform” rating to a “market perform” rating in a research note on Tuesday, May 26th. Nineteen research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $97.33.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.